ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

Kyle Blankenship

Despite immense clinical promise, small cell and gene therapy players have faced a chronic manufacturing bottleneck tied to limited cash and specialized expertise. Born from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

Kyle Blankenship

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Outlook's shares crash as wet AMD drug flunks Phase 3 test

El­e­vate­Bio adds an­oth­er $525M to its war chest as it looks to build on next-gen man­u­fac­tur­ing 'base­cam­p'

Kyle Blankenship

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Outlook's shares crash as wet AMD drug flunks Phase 3 test